Table 2.
Baseline characteristics stratified for the presence of ACPA
| ACPA-positive | p value | ACPA-negative | p value | |||
|---|---|---|---|---|---|---|
| RA patients receiving intensified treatment (n = 92) | RA patients receiving routine care (n = 50) | RA patients receiving intensified treatment (n = 63) | RA patients receiving routine care (n = 72) | |||
| Age, mean (SD) | 50 (12) | 58 (12) | 0.001 | 56 (16) | 63 (16) | 0.019 |
| Female gender, n (%) | 66 (72) | 32 (64) | 0.34 | 40 (64) | 47 (65) | 0.83 |
| Symptom duration < 12 weeks, n (%) | 31 (36) | 12 (27) | 0.31 | 25 (42) | 28 (44) | 0.82 |
| 66-SJC, median (IQR) | 5 (3–10) | 6 (3–8) | 0.73 | 8 (4–15) | 8 (4–14) | 0.96 |
| 68-TJC, median (IQR) | 11 (6–16) | 8 (4–16) | 0.06 | 16 (11–25) | 14 (10–21) | 0.34 |
| ESR, median (IQR) | 29 (16–41) | 30 (14–44) | 0.60 | 19 (9–41) | 31 (11–52) | 0.19 |
| DAS44, median (IQR) | 2.9 (2.5–3.5) | 2.7 (2.4–3.1) | 0.21 | 3.3 (2.7–4.0) | 3.2 (2.6–3.8) | 0.66 |
| RF-positive, n (%) | 81 (88) | 40 (80) | 0.20 | 20 (32) | 18 (25) | 0.39 |
Table depicting baseline characteristics of all patients included in the present study, stratified for ACPA status. Missings were as follows: ACPA (2), TJC (9), SJC (8), ESR (1). RA rheumatoid arthritis, SD standard deviation, SJC swollen joint count, TJC tender joint count, IQR interquartile range, ESR erythrocyte sedimentation rate, ACPA anticitrullinated protein antibody, RF rheumatoid factor